[HTML][HTML] Identification and validation of RB1 as an immune-related prognostic signature based on tumor mutation burdens in bladder cancer
N Liu, T Wu, Y Ma, H Cheng, W Li, M Chen - Anti-Cancer Drugs, 2023 - journals.lww.com
Bladder cancer (BCa) is one of the most common malignant tumors in the urinary system.
Developing effective prognostic gene and exploring the immune cells that affect the …
Developing effective prognostic gene and exploring the immune cells that affect the …
[HTML][HTML] Identification and validation of RB1 as an immune-related prognostic signature based on tumor mutation burdens in bladder cancer
N Liu, T Wu, Y Ma, H Cheng, W Li, M Chen - Anti-Cancer Drugs, 2023 - journals.lww.com
Bladder cancer (BCa) is one of the most common malignant tumors in the urinary system.
Developing effective prognostic gene and exploring the immune cells that affect the …
Developing effective prognostic gene and exploring the immune cells that affect the …
Identification and validation of RB1 as an immune-related prognostic signature based on tumor mutation burdens in bladder cancer
N Liu, T Wu, Y Ma, H Cheng, W Li, M Chen - Anti-Cancer Drugs, 2022 - ingentaconnect.com
Bladder cancer (BCa) is one of the most common malignant tumors in the urinary system.
Developing effective prognostic gene and exploring the immune cells that affect the …
Developing effective prognostic gene and exploring the immune cells that affect the …
[HTML][HTML] Identification and validation of RB1 as an immune-related prognostic signature based on tumor mutation burdens in bladder cancer
N Liu, T Wu, Y Ma, H Cheng, W Li, M Chen - Anti-Cancer Drugs, 2023 - ncbi.nlm.nih.gov
Bladder cancer (BCa) is one of the most common malignant tumors in the urinary system.
Developing effective prognostic gene and exploring the immune cells that affect the …
Developing effective prognostic gene and exploring the immune cells that affect the …
Identification and validation of RB1 as an immune-related prognostic signature based on tumor mutation burdens in bladder cancer
N Liu, T Wu, Y Ma, H Cheng, W Li… - Anti-cancer …, 2023 - pubmed.ncbi.nlm.nih.gov
Bladder cancer (BCa) is one of the most common malignant tumors in the urinary system.
Developing effective prognostic gene and exploring the immune cells that affect the …
Developing effective prognostic gene and exploring the immune cells that affect the …
Identification and validation of RB1 as an immune-related prognostic signature based on tumor mutation burdens in bladder cancer.
N Liu, T Wu, Y Ma, H Cheng, W Li, M Chen - Anti-cancer Drugs, 2022 - europepmc.org
Bladder cancer (BCa) is one of the most common malignant tumors in the urinary system.
Developing effective prognostic gene and exploring the immune cells that affect the …
Developing effective prognostic gene and exploring the immune cells that affect the …
[引用][C] Identification and validation of RB1 as an immune-related prognostic signature based on tumor mutation burdens in bladder cancer
N Liua, T Wua, Y Maa, H Chenga, W Lia… - Anti-Cancer …, 2023 - europepmc.org
According to the latest research, bladder cancer (BCa) is known as the 11th most common
malignant tumor all over the world [1]. In Europe and America, the mortality caused by BCa …
malignant tumor all over the world [1]. In Europe and America, the mortality caused by BCa …
Identification and validation of RB1 as an immune-related prognostic signature based on tumor mutation burdens in bladder cancer
N Liu, T Wu, Y Ma, H Cheng, W Li, M Chen - Anti-Cancer Drugs, 2023 - ingentaconnect.com
Bladder cancer (BCa) is one of the most common malignant tumors in the urinary system.
Developing effective prognostic gene and exploring the immune cells that affect the …
Developing effective prognostic gene and exploring the immune cells that affect the …